The landmark clinical dataset came from the Phase 2 trial led by Jastreboff et al., published in the New England Journal of Medicine in 2023
Circulation 129(5):587597 van Bommel EJ, Muskiet MH, van Baar MJ, Tonneijck L, Smits MM, Emanuel AL et al (2019) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
The latest block includes a swathe of smaller companies such as Strut Health, PharmaZee, Lean Rx, and influencer and TV personality Savannah Chrisley's GoodGirlRx that are operating weight-loss programmes based on providing compounded versions of Novo Nordisk's GLP-1 agonists semaglutide and liraglutide and Lilly's dual GIP/GLP-1 agonist tirzepatide
Noom Med exclusively uses compounded versions, while Calibrate offers both options
Here is where the distinction between preclinical and clinical data becomes critical